Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 142440
Corporate User License Price USD 6000
Corporate User License Price INR 427320
Site License Price USD 4000
Site License Price INR 284880
Request a Quote

Report Title

osteosarcoma-pipeline review, h2 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

osteosarcoma-pipeline review, h2 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

osteosarcoma-pipeline review, h2 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

osteosarcoma-pipeline review, h2 2017



Executive Summary

Osteosarcoma-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma-Pipeline Review, H2 2017, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 16, 4, 16 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 2 and 4 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).

-The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)

Reasons to buy

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Osteosarcoma-Overview 7

Osteosarcoma-Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 16

Osteosarcoma-Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 20

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Osteosarcoma-Companies Involved in Therapeutics Development 27

Advaxis Inc 27

Advenchen Laboratories LLC 27

Amgen Inc 28

AntiCancer Inc 28

Arrowhead Pharmaceuticals Inc 29

AVEO Pharmaceuticals Inc 29

Bayer AG 30

Bellicum Pharmaceuticals Inc 30

Boehringer Ingelheim GmbH 31

Bristol-Myers Squibb Company 31

Celldex Therapeutics Inc 32

Cellmid Ltd 32

CorMedix Inc 33

Daiichi Sankyo Company Ltd 33

Eisai Co Ltd 34

Eleison Pharmaceuticals LLC 34

Intezyne Technologies Inc 35

Ipsen SA 35

Isofol Medical AB 36

Johnson & Johnson 36

MacroGenics Inc 37

MD Biosciences GmbH 37

Merck & Co Inc 38

Merck KGaA 38

Novartis AG 39

Oncolys BioPharma Inc 39

Pfizer Inc 40

Teijin Pharma Ltd 40

Osteosarcoma-Drug Profiles 41

12-B80-Drug Profile 41

3D-QM-Drug Profile 42

3D-QMS-Drug Profile 43

A-1R-Drug Profile 44

ADXS-HER2-Drug Profile 46

aldoxorubicin hydrochloride-Drug Profile 50

AM-7209-Drug Profile 68

apatinib-Drug Profile 69

AT-69-Drug Profile 75

AU-101-Drug Profile 76

AV-203-Drug Profile 77

avelumab-Drug Profile 80

axitinib-Drug Profile 91

BMTP-11-Drug Profile 97

CAB-102-Drug Profile 99

Cellular Immunotherapy for GD2 Expressing Solid Tumors-Drug Profile 101

Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma-Drug Profile 103

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology-Drug Profile 104

Celyvir-Drug Profile 105

cisplatin SR-Drug Profile 106

daunorubicin hydrochloride-Drug Profile 108

dihydroartemisinin-Drug Profile 109

DS-5272-Drug Profile 110

enoblituzumab-Drug Profile 111

everolimus-Drug Profile 114

glembatumumab vedotin-Drug Profile 126

ipilimumab + nivolumab-Drug Profile 132

irinotecan hydrochloride-Drug Profile 140

JNJ-7107-Drug Profile 152

lenvatinib mesylate-Drug Profile 155

ligerin-Drug Profile 169

MD-401A-Drug Profile 170

Minnelide-Drug Profile 171

Modufolin-Drug Profile 173

Monoclonal Antibody for Osteosarcoma-Drug Profile 176

Monoclonal Antibody to Inhibit GD2 for Oncology-Drug Profile 177

Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma-Drug Profile 178

OBP-702-Drug Profile 180

Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer-Drug Profile 181

pazopanib hydrochloride-Drug Profile 182

pembrolizumab-Drug Profile 190

radium Ra 223 dichloride-Drug Profile 251

RSF-101-Drug Profile 260

SEN-461-Drug Profile 262

sirolimus albumin-bound-Drug Profile 263

Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma-Drug Profile 265

Small Molecules to Inhibit CaMKII for Osteosarcoma-Drug Profile 266

Small Molecules to Inhibit MDM2 for Osteosarcoma-Drug Profile 267

taurolidine-Drug Profile 268

Vaccine for Osteosarcoma-Drug Profile 269

VIMO-001-Drug Profile 270

Osteosarcoma-Dormant Projects 271

Osteosarcoma-Discontinued Products 273

Osteosarcoma-Product Development Milestones 274

Featured News & Press Releases 274

Appendix 282

Methodology 282

Coverage 282

Secondary Research 282

Primary Research 282

Expert Panel Validation 282

Contact Us 282

Disclaimer 283

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Osteosarcoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Osteosarcoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Osteosarcoma-Pipeline by Advaxis Inc, H2 2017

Osteosarcoma-Pipeline by Advenchen Laboratories LLC, H2 2017

Osteosarcoma-Pipeline by Amgen Inc, H2 2017

Osteosarcoma-Pipeline by AntiCancer Inc, H2 2017

Osteosarcoma-Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017

Osteosarcoma-Pipeline by AVEO Pharmaceuticals Inc, H2 2017

Osteosarcoma-Pipeline by Bayer AG, H2 2017

Osteosarcoma-Pipeline by Bellicum Pharmaceuticals Inc, H2 2017

Osteosarcoma-Pipeline by Boehringer Ingelheim GmbH, H2 2017

Osteosarcoma-Pipeline by Bristol-Myers Squibb Company, H2 2017

Osteosarcoma-Pipeline by Celldex Therapeutics Inc, H2 2017

Osteosarcoma-Pipeline by Cellmid Ltd, H2 2017

Osteosarcoma-Pipeline by CorMedix Inc, H2 2017

Osteosarcoma-Pipeline by Daiichi Sankyo Company Ltd, H2 2017

Osteosarcoma-Pipeline by Eisai Co Ltd, H2 2017

Osteosarcoma-Pipeline by Eleison Pharmaceuticals LLC, H2 2017

Osteosarcoma-Pipeline by Intezyne Technologies Inc, H2 2017

Osteosarcoma-Pipeline by Ipsen SA, H2 2017

Osteosarcoma-Pipeline by Isofol Medical AB, H2 2017

Osteosarcoma-Pipeline by Johnson & Johnson, H2 2017

Osteosarcoma-Pipeline by MacroGenics Inc, H2 2017

Osteosarcoma-Pipeline by MD Biosciences GmbH, H2 2017

Osteosarcoma-Pipeline by Merck & Co Inc, H2 2017

Osteosarcoma-Pipeline by Merck KGaA, H2 2017

Osteosarcoma-Pipeline by Novartis AG, H2 2017

Osteosarcoma-Pipeline by Oncolys BioPharma Inc, H2 2017

Osteosarcoma-Pipeline by Pfizer Inc, H2 2017

Osteosarcoma-Pipeline by Teijin Pharma Ltd, H2 2017

Osteosarcoma-Dormant Projects, H2 2017

Osteosarcoma-Dormant Projects, H2 2017 (Contd..1), H2 2017

Osteosarcoma-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Advaxis Inc

Advenchen Laboratories LLC

Amgen Inc

AntiCancer Inc

Arrowhead Pharmaceuticals Inc

AVEO Pharmaceuticals Inc

Bayer AG

Bellicum Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celldex Therapeutics Inc

Cellmid Ltd

CorMedix Inc

Daiichi Sankyo Company Ltd

Eisai Co Ltd

Eleison Pharmaceuticals LLC

Intezyne Technologies Inc

Ipsen SA

Isofol Medical AB

Johnson & Johnson

MacroGenics Inc

MD Biosciences GmbH

Merck & Co Inc

Merck KGaA

Novartis AG

Oncolys BioPharma Inc

Pfizer Inc

Teijin Pharma Ltd


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person